

SCIENTIFIC PROGRAMME



Programme at a Glance 6

Detailed Scientific Programme

Educational Days

Thursday, September 19

EANO – EORTC Educational Day

Clinical Track. 8

Basic/Translational Track. 9

Educational Day for Nurses and AHPs 10

EANO Meeting 11

Thursday, September 19. 11

Friday, September 20. 12

Saturday, September 21. 19

Sunday, September 22. 23

Side Meetings 24



THURSDAY, SEPTEMBER 19

EANO – EORTC EDUCATIONAL DAY: Clinical Track

Thursday, September 19

Room: Bellecour

08:30 – 08:40

Welcome Address

Martin van den Bent (Rotterdam, NL) on behalf of EANO and EORTC

08:40 – 09:55

Diagnostic developments

Chairs: Dominique Figarella Branger (Marseille, FR), Marta Nowosielski (Innsbruck, AT)

08:40 – 09:05

Clinical applications of the new WHO classification; *Pieter Wesseling (Utrecht, NL)*

09:05 – 09:30

Methylation profiling for clinicians; *David Capper (Berlin, DE)*

09:30 – 09:55

Pitfalls in the radiological assessment of brain tumor therapies; *Marta Nowosielski (Innsbruck, AT)*

09:55 – 10:15

Coffee break

10:15 – 11:25

Current therapies for brain tumor patients;

Chairs: Anthony Chalmers (Glasgow, UK), Emilie Le Rhun (Lille, FR)

10:15 – 10:40

Radiotherapy and alkylating chemotherapy; *Anthony Chalmers (Glasgow, UK)*

10:40 – 11:05

Targeted therapy and immunotherapy; *Martin van den Bent (Rotterdam, NL)*

11:05 – 11:25

Assessing new treatments in Europe; *Vassilis Golfopoulos (Brussels, BE)*

11:25 – 13:00

Clinical trials in neuro-oncology

Chairs: Martin van den Bent (Rotterdam, NL), Wolfgang Wick (Heidelberg, DE)

11:25 – 11:50

Surgical trials; *Manfred Westphal (Hamburg, DE)*

11:50 – 12:15

Gliomas; *Michael Weller (Zurich, CH)*

12:15 – 12:40

CNS metastasis; *Emilie Le Rhun (Lille, FR)*

12:40 – 13:00

Strategies and pitfalls of clinical trial design; *Martin van den Bent (Rotterdam, NL)*

13:00 – 14:00

Lunch break

14:00 – 15:20

Update on rare CNS tumors

Chairs: Asgeir Jakola (Gothenburg, SE), Irene Slavic (Vienna, AT)

14:00 – 14:20

Pilocytic astrocytomas, histone-mutated gliomas, and pleomorphic xanthoastrocytomas
Riccardo Soffietti (Turin, IT)

14:20 – 14:40

Neuronal and neuronal-glial tumors; *Asgeir Jakola (Gothenburg, SE)*

14:40 – 15:00

Neurofibromatosis type 1 and 2; *Irene Slavic (Vienna, AT)*

15:00 – 15:20

Trials in rare brain tumors; *Peter Hau (Regensburg, DE)*

15:20 – 15:40

Coffee Break

15:40 – 17:00

Epilepsy and cognition across tumor types and treatments

Chairs: Joachim Steinbach (Frankfurt, DE), Roberta Rudà (Turin, IT)

15:40 – 16:00

Epilepsy in glial tumors; *Roberta Rudà (Turin, IT)*

16:00 – 16:20

Epilepsy in non-glial tumors; *Joachim Steinbach (Frankfurt, DE)*

16:20 – 16:40

Neurocognitive functioning in primary brain tumors; *Martin Klein (Amsterdam, NL)*

16:40 – 17:00

Cognition in Brain Tumors in children; *Didier Frappaz (Lyon, FR)*



**THURSDAY, SEPTEMBER 19****EANO – EORTC EDUCATIONAL DAY:
Basic/Translational Track**

Thursday, September 19

Room: Gratte-Ciel

- 08:20 – 08:30** **Welcome address**
Simone Niclou (Luxembourg, LU)
- 08:30 – 10:00** **Neuro-oncology breakthroughs in 2018**
Chairs: Pim French (EORTC, Rotterdam, NL) & Simone Niclou (EANO, Luxembourg, LU)
- 08:30 – 09:00 Highlights of 2018 (basic science)
Monika Hegi (Lausanne, CH)
- 09:00 – 09:30 Highlights of 2018 (clinical trials)
Wolfgang Wick (Heidelberg, DE)
- 09:30 – 10:00 Update on the molecular classification of adult gliomas
Francois Ducray (Lyon, FR)
- 10:00 – 10:30 *Coffee break*
- 10:30 – 12:30** **New developments in molecular technologies**
Chairs: Pim French (EORTC, Rotterdam, NL) & Simone Niclou (EANO, Luxembourg, LU)
- 10:30 – 11:00 New developments in paediatric neuro-oncology
Marta Alonso (Pamplona, ES)
- 11:00 – 11:30 Measuring oncogenic signaling pathway activation for precision medicine (OncoSignal)
Anja van de Stolpe (Eindhoven/NL)
- 11:30 – 12:00 Rethinking EGFR as target
Pim French (Rotterdam, NL)
- 12:00 – 12:30 The target landscape of clinical kinase drugs: what is the future of kinase inhibitors?
Bernhard Küster (Munich, DE)
- 12:30 – 13:30 *Lunch break*
- 13:30 – 15:00** **New developments in IDH mutant gliomas**
Chairs: Martine Lamfers (Rotterdam, NL), Houtan Noushmehr (Detroit, US)
- 13:30 – 14:00 Significance of methylator phenotypes
Houtan Noushmehr (Detroit, US)
- 14:00 – 14:30 Oncogenic IDH mutations: a clinical perspective
Marc Sanson (Paris, FR)
- 14:30 – 15:00 Metabolic aspects of IDH mutant gliomas
Daniel Tennant (Birmingham, UK)
- 15:00 – 15:30 *Coffee break*
- 15:30 – 17:00** **Immunotherapy: where next**
Chairs: Martine Lamfers (Rotterdam, NL), Houtan Noushmehr (Detroit, US)
- 15:30 – 16:00 The basics of immunotherapy
Michael Platten (Mannheim, DE)
- 16:00 – 16:30 Microglia and macrophages in brain malignancies
Lisa Sevenich (Frankfurt, DE)
- 16:30 – 17:00 Priming the immune response for checkpoint blockade
Susan Short (Leeds, UK)



THURSDAY, SEPTEMBER 19

EDUCATIONAL DAY FOR NURSES AND AHPS

Thursday, September 19

Room: Tête d'Or 1




- 08:30 – 08:35** **Welcome**
Karin Piil (Copenhagen, DK)
- 08:35 – 08:50** **Introduction to French clinical practice**
Alexandra Redon (Lyon, FR)
- 08:50 – 10:00** **Symptom management**
Chairs: Ingela Oberg (Cambridge, UK), Karin Piil (Copenhagen, DK)
- 08:50 – 09:20 Guide to management of major symptoms in patients with malignant glioma
Terri Armstrong (Bethesda, US)
- 09:20 – 09:40 Interventions for symptom management and improving quality of life – what is the state of the evidence?
Florien Boele (Leeds, UK)
- 09:40 – 10:00 From newly diagnosed to long-term survivorship; *Karin Piil (Copenhagen, DK)*
- 10:00 – 10:30 *Coffee break*
- 10:30 – 12:30** **Surgery and cognitive assessment**
Chairs: Karin Piil (Copenhagen, DK), Aleksandar Stanimirovic (Beograd, RS)
- 10:30 – 11:15 Advances in neurosurgery for brain tumours; *Asgeir Jakola (Gothenburg, SE)*
- 11:15 – 11:45 Threshold for awake glioma surgery: Choosing the right candidate
Aleksandar Stanimirović (Beograd, RS)
- 11:45 – 12:30 Consequences of neurological deficits after tumor surgery
Martin Klein (Amsterdam, NL)
- 12:30 – 13:30 *Lunch break*
- 13:30 – 15:00** **On-going PhD-projects**
Chairs: Petra Hoogendoorn (Amsterdam, NL), Lena Rosenlund (Stockholm, SE)
- 13:30 – 13:50 Shared decision making for patients with recurrent malignant brain tumour
Helle Soerensen Von Essen (Odense, DK)
- 13:50 – 14:10 Supportive care needs of TYA childhood brain tumour survivors and their caregivers: A mixed method study; *Emma Nicklin (Leeds, UK)*
- 14:10 – 14:30 Patient reported outcomes for person-centered care; *Lena Rosenlund (Stockholm, SE)*
- 14:30 – 14:50 Development and testing of an App; Goings-on; *Petra Hoogendoorn (Amsterdam, NL)*
- 14:50 – 15:00 Discussions
- 15:00 – 15:30 *Coffee break*
- 15:30 – 17:00** **Advance care planning and management**
Chairs: Ingela Oberg (Cambridge, UK), Karin Piil (Copenhagen, DK)
- 15:30 – 16:00 Management of adult glioma in nursing practice - Editing a book
Ingela Oberg (Cambridge, UK)
- 16:00 – 16:30 Difficult conversations around a life limiting diagnosis: how to discuss what matters most
Helen Bulbeck (Isle of Wight, UK)
- 16:30 – 16:45 Closing remarks; *Karin Piil (Copenhagen, DK), Alexandra Redon (Lyon, FR)*



THURSDAY, SEPTEMBER 19

EANO MEETING

Thursday, September 19



17:15 – 18:15

Meet the Editor

Room: Bellecour

Chair: Wolfgang Wick (Heidelberg, DE)

17:15 – 17:35

Neuro-Oncology

Ken Aldape (Toronto, CA)

17:35 – 17:55

Neuro-Oncology Advances

Gelareh Zadeh (Toronto, CA)

17:55 – 18:15

Neuro-Oncology Practice

Susan Chang (San Francisco, US)



17:15 – 18:15

EANO Women in Neuro-oncology

Room: Grette-Ciel

Chairs: Linda Dirven (Rotterdam, NL), Simone Niclou (Luxemburg, LU)

17:15 – 17:20

Introduction

Martin van den Bent (Rotterdam, NL)

17:20 – 17:32

What is happening in the US?

Susan Chang (San Francisco, US)

17:32 – 17:47

Results of the EANO gender issue committee survey

Emilie Le Rhun (Lille, FR)

17:47 – 18:00

Discussion

19:00 – 21:30

EANO Networking Evening

Lyon City Hall - Hôtel de Ville

Spend a nice evening with your colleagues while enjoying finger food and drinks.

Please note that advance registration is mandatory in order to receive a ticket!

Limited attendance, individual arrival.

See page 36 for further details.



FRIDAY, SEPTEMBER 20


EANO MEETING

Friday, September 20

- 08:00 – 09:00** **Meet the Expert 1: Brain metastases**
Room: Amphithéâtre
Chairs: Anna Berghoff (Vienna, AT), Riccardo Soffietti (Turin, IT)
- 08:00 – 08:20 **Immune control of brain metastases**
Mihaela Lorger (Leeds, UK)
- 08:20 – 08:40 **Clinical trials in brain metastases**
Anna Berghoff (Vienna, AT)
- 08:40 – 09:00 **Microenvironment in brain metastases**
Manuel Valiente (Madrid, ES)
- 08:00 – 09:00** **Meet the expert 2: Nursing and AHP perspective**
Room: Bellecour
Chairs: Florian Boele (Leeds, UK), Karin Piil (Copenhagen, DK)
- 08:00 – 08:20 **Multidisciplinary teamwork in the management of adult glioma**
Ingela Oberg (Cambridge, UK)
- 08:20 – 08:40 **Monitoring, understanding and managing cognitive problems in cancer patients without CNS disease: putting knowledge into practice**
Sanne Schagen (Amsterdam, NL)
- 08:40 – 09:00 **Mental capacity framework**
Heather Ayles (Cambridge, UK)
- 08:00 – 09:00** **Meet the Expert 3: Local therapies**
Room: Gratte-Ciel
Chairs: Clemens Dirven (Rotterdam, NL), Jaime Gállego Pérez de Larraya (Pamplona, ES)
- 08:00 – 08:20 **Virotherapy**
Annick Desjardins (Duke, US)
- 08:20 – 08:40 **CAR T cells**
Hideho Okada (San Francisco, US)
- 08:40 – 09:00 **Disrupting the BBB**
Ahmed Idbaih (Paris, FR)
- 09:00 – 10:30** **Oral Session 1: Liquid biomarker**
Room: Amphithéâtre
Chairs: Oliver Hanemann (Plymouth, UK), Joachim Steinbach (Frankfurt, DE)
- 09:00 – 09:22 **Tumor-educated platelets**
Tom Würdinger (Amsterdam, NL)
- 09:22 – 09:28 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients
Maximilian Mair (Vienna, AT)
- 09:28 – 09:34 Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Jian-Guo Zhou (Zunyi City, CN)
- 09:34 – 09:40 Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis
Guido Ahle (Colmar, FR)
- 09:40 – 09:46 Liquid biopsy of the CSF in a series of GBM patients: preliminary results.
Francesco Bruno (Turin, IT)
- 09:46 – 09:52 Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers
Houtan Noushmehr (Detroit, US)

**FRIDAY, SEPTEMBER 20**



- 09:52 – 09:58 Peripheral blood immune profiles at first recurrence of IDH wild type glioblastoma after standard chemoradiotherapy predict overall survival: secondary analyses of the phase II DIRECTOR trial
Hans-Georg Wirsching (Zurich, CH)
- 09:58– 10:04 Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls.
Emeline Tabouret (Marseille, FR)
- 10:04– 10:26 **Cell-free tumor DNA**
Joan Seoane (Barcelona, ES)
- 09:00 – 10:30 Oral Session 2: Spinal tumors**
Room: Bellecour
Chairs: Federico Pessina (Milan, IT), Gelareh Zadeh, (Toronto, CA)
- 09:00 – 09:26 **Surgical approaches to intramedullary tumors**
Jörg Tonn (Munich, DE)
- 09:26 – 09:52 **Novel concepts of radiotherapy of spinal tumors**
Giuseppe Minniti (Rome, IT)
- 09:52 – 09:59 Incidence patterns for primary spinal cord ependymomas in adults: a Surveillance, Epidemiology, and End Results study
Weitao Man (Beijing, CN)
- 09:59 – 10:06 Chemotherapy for spinal gliomas in adults
Dorothee Gramatzki (Zurich, CH)
- 10:06 – 10:13 Relevance of Neurofibromatosis type 1 and schwannomatosis in extramedullary spine tumors
Marica Eoli (Milan, IT)
- 10:13 – 10:20 Using FineSA MRI for early detection of Spinal Metastases
Ayako Niina (Cardiff, UK)
- 10:20 – 10:30 Discussion time
- 09:00 – 10:30 Oral Session 3: Value of patient-reported outcomes**
Room: Gratte-Ciel
Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL)
- 09:00 – 09:22 **Clinical implementation of patient-reported outcomes in neuro-oncology**
Mirjam Renovanz (Tübingen, DE)
- 09:22 – 09:44 **Neurocognitive outcome parameters – how much do we need?**
Linda Dirven (Leiden, NL)
- 09:44 – 09:50 Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients
Pim van der Meer (Leiden, NL)
- 09:50 – 09:56 Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study.
Mirjam Renovanz (Tuebingen, DE)
- 09:56 – 10:02 Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III
Quirien Oort (Amsterdam, NL)
- 10:02 – 10:08 Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status.
Didier Frappaz (Lyon, FR)
- 10:08 – 10:14 Prescription medications in glioma patients and the prevalence of depression, anxiety and subjective cognitive impairment
Pim van der Meer (Leiden, NL)
- 10:14 – 10:20 Prediagnostic symptoms and signs of adult glioma: the patients' view
Marthe Peeters (Leiden, NL)
- 10:20 – 10:30 Discussion time
- 10:30 – 11:05 *Coffee break*







FRIDAY, SEPTEMBER 20

- 11:10 – 11:20 Meeting opening and presidential address**
Room: Amphithéâtre
Chairs: Jérôme Honnorat (Lyon, FR), Martin van den Bent (Rotterdam, NL)
- 11:20 – 12:50 Plenary Session 1: Low grade glioma**
Room: Amphithéâtre
Chairs: François Ducray (Paris, FR), Sevin Turcan (Heidelberg, DE)
- 11:20 – 11:50 **Single cell resolution of low grade glioma**
Itay Tirosh (Rehovot, IL)
- 11:50 – 12:20 **Challenges in the treatment of low grade glioma**
Jean-Yves Delattre (Paris, FR)
- 12:20 – 12:30 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
Dominique Figarella-Branger (Marseille, FR)
- 12:30 – 12:40 Multiparametric assessment of factors influencing 2 HG accumulation in diffuse brain gliomas
Lucia Nichelli (Paris, FR)
- 12:40 – 12:45 Discussion led by: Martin van den Bent (Rotterdam, NL)
- 12:45 – 12:50 Q&A
- 12:50 – 14:20 *Lunch break*
- Corporate Lunch Symposium and Corporate Lunch Workshop**
 For details see page 31
- 13:20 – 14:20 Workshop 1: Mentoring session on “How to plan your career in Neuro-Oncology”**
Room: Tête d’Or Lounge
 Pre-registration required, no fee.
 One-hour face-to-face discussion with 6 mentors.
 Please come to the registration desk to see if seats are still available.
 In case you booked this workshop, there are small initials on your badge.
- Table 1: How to plan your career in Neuro-Oncology: Clinical Neuro-Oncology
Mentor: Riccardo Soffietti
- Table 2: How to plan your career in Neuro-Oncology: Clinical Neuro-Oncology
Mentor: Matthias Preusser
- Table 3: How to plan your career in Neuro-Oncology: Laboratory Science
Mentor: Manuel Valiente
- Table 4: How to plan your career in Neuro-Oncology: Laboratory Science
Mentor: Monika Hegi
- Table 5: How to plan your career in Neuro-Oncology: Neurosurgery
Mentor: Lorenzo Bello
- Table 6: How to plan your career in Neuro-Oncology: Neurosurgery
Mentor: Miriam Ratliff
- 13:20 – 14:20 Workshop 2: Handling high throughput data**
Room: Tête d’Or 2
Chairs: Olivier Ayrault (Paris, FR), Carina Thomé (Heidelberg, DE)
 Pre-registration required, no fee.
 Please come to the registration desk to see if seats are still available.
 In case you booked this workshop, there is a mark with the workshop number on your badge.
- 13:20 – 13:25 *Itay Tirosh (Rehovot, IL)*
- 13:25 – 13:30 *Sevin Turcan (Heidelberg, DE)*
- 13:30 – 13:35 *Olivier Ayrault (Paris, FR)*
- 13:35 – 14:15 Discussion
- 14:15 – 14:20 Summary



FRIDAY, SEPTEMBER 20

- 14:25 – 15:55** **Oral Session 4: Early clinical trials**
Room: Amphithéâtre
Chairs: Michael Weller (Zurich, CH), Emeline Tabouret (Marseille, FR)
- 14:25 – 14:44 **How to test targeted therapies in neuro-oncology**
Tracy Batchelor (Boston, US)
- 14:44 – 15:03 **Trial design challenges in pediatric neuro-oncology**
Sabine Müller (San Francisco, US)
- 15:03 – 15:22 **NCI-CONNECT**
Mark Gilbert (Bethesda, US)
- 15:22 – 15:30 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway.
Didier Frappaz (Lyon, FR)
- 15:30 – 15:38 Phase 0 trial of Ceritinib in brain metastasis and recurrent glioblastoma
Nader Sanai (Phoenix, US)
- 15:38 – 15:46 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials
Capucine Baldini (Villejuif, FR)
- 15:46 – 15:54 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma : Results of the phase I part of the phase I/II STERIMGLI trial.
Elizabeth Cohen-Jonathan Moyal (Toulouse, FR)
- 14:25 – 15:55** **Oral Session 5: DIPG**
Room: Bellecour
Chairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK)
- 14:25 – 14:50 **Heterogeneity in DIPG**
Javad Nazarian (Zurich, CH)
- 14:50 – 15:15 **Overcoming resistance in DIPG**
Chris Jones (London, UK)
- 15:15 – 15:23 Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs
Marta Alonso (Pamplona, ES)
- 15:23 – 15:31 Distinct immune and molecular profile of pediatric and adult diffuse midline gliomas
Kavneet Kaur (New Delhi, IN)
- 15:31 – 15:39 Quantitative signaling pathway analysis of Diffuse Intrinsic Pontine Glioma identifies two subtypes, respectively high TGF β /MAPK-AP1 and high PI3K/HH pathway activity, which are potentially clinically actionable
Anja van de Stolpe (Eindhoven, NL)
- 15:39 – 15:47 Characteristics of adult diffuse H3K27M-mutant gliomas at recurrence
Khalil Hodroj (Lyon, FR)
- 15:47 – 15:55 Characteristics of high-grade gliomas with H3 G34 mutation in adults
Thiébaud Picart (Bron, FR)





FRIDAY, SEPTEMBER 20

14:25 – 15:55 **Oral Session 6: Metabolic pathways** **Room: Gratte-Ciel**

Chairs: Anthony Chalmers (Glasgow, UK), Simone Niclou (Luxembourg, LU)

14:25 – 14:45 **Mitochondria and energy metabolism in glioblastoma** *Heiko Wurdak (Leeds, UK)*

14:45 – 15:05 **Inhibiting immunosuppressive IDO1 in patients with malignant glioma – a moving target that changes with treatment, cell of origin, and aging** *Lijie Zhai (Chicago, US)*


15:05 – 15:14 Targeting Purine Metabolism to Overcome Therapeutic Resistance in Glioblastoma *Atique Ahmed (Chicago, US)*

15:14 – 15:23 Loss of CYP46A1 directs altered cholesterol homeostasis and opens therapeutic opportunities for glioblastoma *Mingzhi Han (Bergen, NO)*

15:23 – 15:32 The complex role of lactate dehydrogenases in glioblastoma development *Thomas Daubon (Pessac, FR)*

15:32 – 15:41 The hypoxia-induced glioma derived exosome miRNA-199a-3p promotes glioma cells proliferation and increased ischemic injury of the para-tumor neurons by inhibiting mTOR pathway – A pivotal ischemic mechanism in the proliferation and growth of glioma *Jian-Lan Zhao (Shanghai, CN)*

15:41 – 15:50 ERGO2: A prospective randomized trial of a 9-day schedule of calorically restricted ketogenic diet and fasting or standard diet in addition to re-irradiation for malignant glioma *Martin Voss (Frankfurt, DE)*



16:05 – 17:35 **Oral Session 7: QoL** **Room: Amphithéâtre**

Chairs: Linda Dirven (Leiden, NL), Andrea Pace (Rome, IT)

16:05 – 16:25 **Challenges in survivorship in ependymoma** *Terri Armstrong (Bethesda, US)*

16:25 – 16:45 **How to standardize assessment and analysis of QoL data** *Martin Taphoorn (Leiden, NL)*

16:45 – 16:51 Impact of the addition of Rituximab to standard therapy with high dose methotrexate on health-related quality of life in primary central nervous system lymphoma patients *Matthijs van der Meulen (Rotterdam, NL)*

This presenter will receive the award for the best abstract in "Patient-related outcomes" during the session.

16:51 – 16:57 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making *Marijke Coomans (Leiden, NL)*

16:57 – 17:03 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients *Giuseppe Lombardi (Padova, IT)*

17:03 – 17:09 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM) *Marijke Coomans (Leiden, NL)*



17:09 – 17:15 Healthcare utilization, medication use, and productivity loss in glioma patients with depressive symptoms and their family caregivers *Florien Boele (Leeds, UK)*

17:15 – 17:21 Socioeconomic burden and associations with quality of life in meningioma patients *Hans-Georg Wirsching (Zurich, CH)*

17:21 – 17:27 Educational program for caregivers of patients with brain tumors: AGAPE *Elodie Vauléon (Rennes, FR)*

FRIDAY, SEPTEMBER 20

- 16:05 – 17:35** **Oral Session 8: Meningeoma**
Room: Bellecour
Chairs: Felix Sahm (Heidelberg, DE), Jörg Tonn (Munich, DE)
- 16:05 – 16:25 **Molecular classifications of meningioma – how much detail do we need?**
Felix Sahm (Heidelberg, DE)
- 16:25 – 16:45 **Clinical Trial Designs in Meningioma**
Matthias Preusser (Vienna, AT)
- 16:45 – 16:51 A phase 0/2 clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients
Nader Sanai (Phoenix, US)
- 16:51 – 16:57 Risk stratification in chordoid meningioma depends on mutation status and epithelial differentiation
Adriana Olar (Charleston, US)
- 16:57 – 17:03 Gamma knife radiosurgery for large meningiomas: 10 years of experience
Khaled Abdel Karim (Cairo, EG)
- 17:03 – 17:09 Impact of brain invasion assessment on outcome in intracranial grade II meningiomas
Thiébaud Picart (Bron, FR)
- 17:09 – 17:15 How to assess meningioma therapy activity: The CEVOREM independent central review experience
Thomas Graillon (Marseille, FR)
- 17:15 – 17:21 Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
Emilie Le Rhun (Lille, FR)
- 17:21 – 17:27 Targeting Pi3k-Akt-mTOR and MAPKinase pathways in aggressive meningiomas: in vitro study.
Gregoire Mondielli (Marseille, FR)
- 17:27 – 17:33 Modified chromatin histone marks at noncoding elements are associated with aggressive meningioma subtype
Houtan Noushmehr (Detroit, US)
- 16:05 – 17:35** **Oral Session 9: Omics in neuro-oncology**
Room: Gratte-Ciel
Chairs: Lucy Stead (Leeds, UK), David Capper (Berlin, DE)
- 16:05 – 16:25 **Uncovering heterogeneity of glioblastoma by epigenomics**
Johanna Klughammer (Vienna, AT)
- 16:25 – 16:45 **Value of phosphoproteomics for classification and target discovery**
Olivier Ayrault (Paris, FR)
- 16:45 – 16:51 Clinical significance of hypermutation in gliomas
Mehdi Touat (Boston, US)
- 16:51 – 16:57 Radiomics analysis of lower-grade gliomas, a POLA Network study.
Nadia Younan (Paris, FR)
This presenter will receive the award for the best abstract in "Clinical sciences" during the session.
- 16:57 – 17:03 Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusion
Alberto Picca (Pavia, IT)
- 17:03 – 17:09 The added value of radiomics to a clinical prognostic model in patients with low-grade glioma
Michiel van Riel (Rotterdam, NL)
- 17:09 – 17:15 Evidence that adult glioblastoma adapts to standard therapy through chromatin remodeling
Lucy Stead (Leeds, UK)
- 17:15 – 17:21 Diagnosis of pseudoprogression using FET PET radiomics
Philipp Lohmann (Juelich, DE)
- 17:21 – 17:27 Telomere length, TERTp mutation and ALT status in adult diffuse gliomas
Cristina Alina Birzu (Paris, FR)
- 17:27 – 17:33 Genomic landscape of medulloblastoma in adults
Tobias Goschzik (Bonn, DE)





FRIDAY, SEPTEMBER 20

17:45 – 19:15 **Poster Viewing with Wine & Cheese**

Topics:

- P01 Liquid Biomarkers
- P02 Spinal tumors
- P03 Patient-reported outcomes
- P04 Low grade glioma
- P05 Early clinical trials
- P06 DIPG
- P07 Metabolic pathways
- P08 QoL/QoD
- P09 Meningeoma
- P10 Neuroimmunology
- P11 Preclinical neuro-oncology
- P12 Immunotherapy




19:30 – 23:30 **Youngsters Networking Event Marriott Cité Internationale**

Join the EANO Youngsters Networking Event and socialise with other young scientist and enjoy a nice evening with drinks and food.

The attendance is limited to PhD students.



Tickets will be sold on first-come-first-served basis.

See page 37 for further details.



**SATURDAY, SEPTEMBER 21****Saturday, September 21**

- 08:00 – 09:00** **Wake-Up Session 1: PCNSL**
Room: Amphithéâtre
Chair: Uwe Schlegel (Bochum, DE), Jacoline Bromberg (Rotterdam, NL)
- 08:00 – 08:20 **Management of the elderly**
Khe Hoang Xuan (Paris, FR)
- 08:20 – 08:40 **Novel agents for PCNSL**
Lakshmi Nayak (Boston, US)
- 08:40 – 09:00 **Evidence-based treatment of PCNSL – where do we stand?**
Jacoline Bromberg (Rotterdam, NL)
- 08:00 – 09:00** **Wake-Up Session 2: EANM-EANO – Session – PET Imaging**
Room: Bellecour
Chairs: Jörg Tonn (Munich, DE), Ian Law (Copenhagen, DK)
- 08:00 – 08:20 **PET imaging of brain metastases**
Norbert Galldiks (Cologne, DE)
- 08:20 – 08:40 **PET imaging in meningiomas**
Ian Law (Copenhagen, DK)
- 08:40 – 09:00 **PET imaging for decision making in brain tumor surgery**
Niklas Thon (Munich, DE)
- 08:00 – 09:00** **Wake-Up Session 3: Microenvironment**
Room: Gratte-Ciel
Chairs: Pim French (Rotterdam, NL), Marc Sanson (Paris, FR)
- 08:00 – 08:20 **Glioma-associated macrophages – friend or foe?**
Leila Akkari (Amsterdam, NL)
- 08:20 – 08:40 **Cellular and functional heterogeneity within the brain metastasis microenvironment**
Manuel Valiente (Madrid, ES)
- 08:40 – 09:00 **Microenvironmental heterogeneity in glioblastoma**
Antonio Iavarone (New York, US)
- 09:10 – 10:30** **Joint EAN-EANO symposium on neuroimmunology**
Room: Amphithéâtre
Chairs: Jérôme Honnorat (Lyon, FR) (EANO), Riccardo Soffietti (Turin, IT) (EAN)
- 09:10 – 09:35 **Paraneoplastic syndromes**
Francesc Graus (Barcelona, ES)
- 09:35 – 09:55 **Neurological complications of cancer**
Jérôme Honnorat, (Lyon, FR)
- 09:55 – 10:03 Specific genetic alterations of breast tumors lead to Yo paraneoplastic cerebellar syndromes
Virginie Desestret (Lyon, FR)
- 10:03 – 10:11 Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era
Alberto Vogrig (Lyon, FR)
- 10:11 – 10:19 Autoimmune encephalitis as immune related adverse event (irAE) of check point inhibitors (CPI) not so rare as we thought.
Alisa Taliansky (Ramat-Gan, IL)
- 10:19 – 10:27 Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: A French neurological multi-center survey.
Catherine Belin (Paris, FR)





SATURDAY, SEPTEMBER 21

09:10 – 10:30 **Pro-Con Session 1: Controversies in imaging and radiotherapy** **Room: Bellecour**


Chairs: Elizabeth Cohen-Jonathan-Moyal (Toulouse, FR), Marilena Theodorou (Nicosia, CY)

Protons are standard of care

- 09:10 – 09:20 Pro: *Damien Weber (Zurich, CH)*
 09:20 – 09:30 Con: *Stephanie Combs (Munich, DE)*
 09:30 – 09:50 Discussion

RANO/iRANO is sufficient for determining pseudoprogression

- 09:50 – 10:00 Pro: *Olivier Chinot (Marseille, FR)*
 10:00 – 10:10 Con: *Wolfgang Wick (Heidelberg, DE)*
 10:10 – 10:30 Discussion



09:10 – 10:30 **Pro-Con Session 2: Controversies in molecular markers** **Room: Gratte-Ciel**


Chairs: Michael Weller (Zurich, CH), Lakshmi Nayak (Boston, US)

MGMT-based treatment decisions

- 09:10 – 09:20 Pro: *Tobias Kessler (Heidelberg, DE)*
 09:20 – 09:30 Con: *Ulrich Herrlinger (Bonn, DE)*
 09:30 – 09:50 Discussion

Targeted treatment decisions in recurrent glioblastoma

- 09:50 – 10:00 Pro: *Colin Watts (Birmingham, UK)*
 10:00 – 10:10 Con: *Antonella Castellano (Milan, IT)*
 10:10 – 10:30 Discussion



10:30 – 11:00 *Coffee break*



11:00 – 12:30 **Oral Session 10: Highlights from clinical abstracts** **Room: Amphithéâtre**

Chairs: Amelie Darlix (Montpellier, FR), Tracy Batchelor (Boston, US)

- 11:00 – 11:15 Survival analysis of IDH wildtype astrocytomas with molecular features of glioblastoma, WHO grade IV
Corneliu Tesileanu (Rotterdam, NL)
- 11:15 – 11:30 Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, non-interventional study in European clinical practice
Roberta Rudà (Turin, IT)
- 11:30 – 11:45 Primary therapy and survival in over 70-year-old patients with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Matthijs van der Meulen (Rotterdam, NL)
- 11:45 – 12:00 Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for leptomeningeal metastasis from breast cancer - a randomized study. Final results
Emilie Le Rhun (Lille, FR)
- 12:00 – 12:15 Outcome of unresectable de novo IDH wild-type GBM: A decade analysis of factors influencing survival.
Alhafidz Hamdan (Glasgow, UK)
- 12:15 – 12:30 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study
Adrew Lassman (New York, US)

**SATURDAY, SEPTEMBER 21**

- 11:00 – 12:30** **Oral Session 11: EANO / SNO Session**
Room: Bellecour
Chairs: Susan Chang, (San Francisco, US), Martin van den Bent (Rotterdam, NL)
- 11:00 – 11:15 **New insights into signaling pathways in leptomeningeal metastasis**
Adrienne Boire (New York, US)
- 11:15 – 11:30 **Vaccines for gliomas**
Michael Platten (Mannheim, DE)
- 11:30 – 11:45 **Modelling glioma**
Simone Niclou (Luxembourg, LU)
- 11:45 – 12:00 **Novel aspects of IDH1 as a therapeutic target**
Gelareh Zadeh (Toronto, CA)
- 12:00 – 12:15 **Obtaining evidence for targeted treatment in glioblastoma subgroups**
Wolfgang Wick (Heidelberg, DE)
- 12:15 – 12:30 **Imaging in Immunooncology – beyond iRANO**
Patrick Wen (Boston, US)
- 11:00 – 12:30** **Oral Session 12: Highlights from preclinical abstracts**
Room: Gratte-Ciel
Chairs: Anna Berghoff (Vienna, AT), Rolf Bjerkvig (Bergen, NO)
- 11:00 – 11:15 Editing of IDH1 R132H mutation in human induced pluripotent stem cells to investigate tumor genesis in glioma
Alexander Köpp (Dresden, DE)
- 11:15 – 11:30 Targeting epigenetic pathways in the treatment of recurrent high-grade glioma
Ann-Christin Hau (Luxembourg, LU)
- 11:30 – 11:45 L3MBTL3 is a novel suppressor of medulloblastoma tumorigenesis.
Jean-Francois Rual (Ann Arbor, US)
- 11:45 – 12:00 In vivo dynamics and targeting of vessel co-option in glioma
Giorgio Seano (Orsay, FR)
- 12:00 – 12:15 Small GTPase RHOE/RND3, a new critical regulator of NF- κ B signaling in glioblastoma multiforme?
Baohui Liu (Wuhan, CN)
- 12:15 – 12:30 Intracranial GBM PDX Mutations Induced by Temozolomide Treatment
Charles David James (Chicago, US)
- 12:30 – 14:00 *Lunch break*
- Corporate Lunch Symposium**
For details see page 31
- 13:00 – 14:00** **Workshop 3: Preclinical Models**
Room: Tête d'Or 2
Chairs: Tobias Weiss (Zurich, CH), Anna Golebiewska (Luxemburg, LU)
Pre-registration required, no fee.
Please come to the registration desk to see if seats are still available.
In case you booked this workshop, there is a mark with the workshop number on your badge.
- 13:00 – 13:05 *Simone Niclou (Luxembourg, LU)*
- 13:05 – 13:10 *Heiko Wurdak (Leeds, UK)*
- 13:10 – 13:15 *Tobias Weiss (Zurich, CH)*
- 13:15 – 13:55 Discussion
- 13:55 – 14:00 Summary





SATURDAY, SEPTEMBER 21

13:00 – 14:00 **Workshop 4: Clinical trial design** **Room: Tête d'Or Lounge**

Chairs: Marjolein Geurts (Utrecht, NL), Antoine Carpentier (Paris, FR)

Pre-registration required, no fee.

Please come to the registration desk to see if seats are still available.

In case you booked this workshop, there is a mark with the workshop number on your badge.

13:00 – 13:05 *Antoine Carpentier (Paris, FR)*

13:05 – 13:10 *Sabine Müller (San Francisco, US)*

13:10 – 13:15 *Martin van den Bent (Rotterdam, NL)*

13:15 – 13:55 Discussion

13:55 – 14:00 Summary

14:05 – 15:35 **Plenary Session 2: Immunotherapy** **Room: Amphithéâtre**

Chairs: Anna Berghoff (Vienna, AT), Patrick Roth (Zurich, CH)

14:05 – 14:35 **Modulating the vascular immune axis to improve glioma therapy**

Gabriele Bergers (Leuven, BE)

14:35 – 15:05 **Target antigens in gliomas**

Wolfgang Wick (Heidelberg, DE)

15:05 – 15:15 Exploiting the DNAM-1 system for chimeric antigen receptor (CAR) T cell therapy of glioblastoma
Tobias Weiss (Zurich, CH)

15:15 – 15:25 Pembrolizumab (PEM) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (dMMR): an observational study

Guiseppe Lombardi (Padova, IT)

15:25 – 15:30 Discussion led by: Valerie Dutoit (Geneva, CH)

15:30 – 15:35 Q&A

15:45 – 17:15 **Poster Viewing with Wine & Cheese**

Topics:

P13 Omics in neuro-oncology

P14 Clinical neuro-oncology

17:15 – 18:00 **Corporate Symposium**

For details see page 31

18:15 – 23:00 **EANO XIV Evening**

Enjoy a wonderful evening with a seated dinner with your colleagues and friends.

Please note that seats are limited, and tickets can only be bought in advance.

Boarding is near the conference venue.

See page 37 for further details.



SUNDAY, SEPTEMBER 22

Sunday, September 22

- 08:30 – 09:30** **EANO Youngsters Session**
Room: Amphithéâtre
Chairs: Matthias Preusser (Vienna, AT), Alessia Pellerino (Torino, IT)
- 08:30 – 08:45 **How to write a successful paper**
Matthias Preusser (Vienna, AT)
- 08:45 – 09:00 **Dos and Don'ts in basic science – how to make your basic science project count**
Michael Platten (Mannheim, DE)
- 09:00 – 09:15 **What to expect and not to expect from your PostDoc time**
Georg Widhalm (Vienna, AT)
- 09:15 – 09:30 **Why Neuro-Oncology has a great work life balance**
Jacoline Bromberg (Rotterdam, NL)
- 09:30 – 10:30** **General Assembly**
- 10:30 – 11:00 *Coffee break*
- 11:00 – 11:30** **Progress in neuro-oncology 2019: strategy of the EORTC Brain Tumor Group**
Room: Amphithéâtre
Michael Weller (Zurich, CH)
- 11:30 – 12:30** **Plenary Session 3: Hot Topics / Late Breaking Abstracts**
Room: Amphithéâtre
Chairs: Roberta Rudà (Turin, IT), Matthias Preusser (Vienna, AT)
- 11:30 – 11:40 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
Ingo Mellinghoff (New York, US)
- 11:40 – 11:50 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser (Vienna, AT)
- 11:50 – 12:00 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion
Corneliu Tesileanu (Rotterdam, NL)
- 12:00 – 12:10 Intrinsic tumor plasticity in Glioblastoma allows for recreation of stem like-states and efficient tumor cell adaptation to new microenvironments
Anna Golebiewska (Luxembourg, LU)
This presenter will receive the award for the best abstract in "Pre-clinical sciences" during the session.
- 12:10 – 12:20 Efficacy and safety of selinexor in recurrent glioblastoma
Andrew Lassman (New York, US)
- 12:20 – 12:30 Targeting GSK-3 activity promotes mitotic catastrophe via centrosome destabilisation and enhances the effect of radiotherapy in glioma models
Susan Short (Leeds, UK)
- 12:30 – 12:45** **Closing remarks**



SIDE MEETINGS

ALL SIDE MEETINGS ARE CLOSED MEETINGS.

As per date of printing.

Thursday, September 19

07:00 – 08:00	RANO collaborative outcomes working group update and planning meeting	Tête d'Or 2
13:00 – 14:00	EORTC-1608: F2F meeting Adastra & EORTC	Tete d'Or 2
14:30 – 15:30	WFNOS website editorial board meeting	Tete d'Or 2
15:30 – 17:00	EANO future venues meeting	Tête d'Or 2
17:15 – 18:15	EORTC-BTC translational research committee meeting	Tête d'Or 1
17:15 – 18:15	EORTC meningioma committee meeting	Tête d'Or Lounge
17:30 – 18:30	1709 investigator meeting	Tête d'Or 2

Friday, September 20

09:30 – 11:00	EORTC 1608 investigator meeting	Tête d'Or 2
11:00 – 11:30	EANO guideline committee meeting	Tête d'Or 2
12:00 – 13:00	EORTC 1419 meeting	Tête d'Or 2
15:00 – 16:00	WFNOS general assembly	Tête d'Or 2
16:00 – 17:00	EANO national societies meeting	Tête d'Or 2
17:45 – 18:30	Meet the sponsors meeting	Tête d'Or 2

Saturday, September 21

09:00 – 10:30	EANO palliative care task force group meeting	Tête d'Or Lounge
10:00 – 12:00	BMS meeting	Tête d'Or 2
12:00 – 13:00	EANO educational committee meeting	Tête d'Or Lounge
15:30 – 16:30	Euracan instead of Eurocan	Tête d'Or 2
15:45 – 16:15	EORTC-1320: F2F meeting	Tête d'Or Lounge

